Alpha-1,2-Mannosyltransferase ALG9
Das ALG9-Gen kodiert ein Protein, welches für die Glykosilierung von Proteinen mitverantwortlich ist. Mutationen sind für autosomal rezessive Glycosilierungsstörungen vom Typ 1L und das Gillessen-Kaesbach-Nishimura-Syndrom verantwortlich.
Gentests:
Klinisch |
Untersuchungsmethoden |
Familienuntersuchung |
Bearbeitungszeit |
5 Tage |
Probentyp |
genomische DNS |
Verknüpfte Erkrankungen:
Referenzen:
1. |
Frank CG et al. (2004) Identification and functional analysis of a defect in the human ALG9 gene: definition of congenital disorder of glycosylation type IL.
|
2. |
Weinstein M et al. (2005) CDG-IL: an infant with a novel mutation in the ALG9 gene and additional phenotypic features.
|
3. |
Tham E et al. (2016) A novel phenotype in N-glycosylation disorders: Gillessen-Kaesbach-Nishimura skeletal dysplasia due to pathogenic variants in ALG9.
|
4. |
Baysal BE et al. (1998) Bipolar affective disorder partially cosegregates with a balanced t(9;11)(p24;q23.1) chromosomal translocation in a small pedigree.
|
5. |
Baysal BE et al. (2002) A mannosyltransferase gene at 11q23 is disrupted by a translocation breakpoint that co-segregates with bipolar affective disorder in a small family.
|
6. |
Orphanet article
Orphanet ID 119629
|
7. |
NCBI article
NCBI 79796
|
8. |
OMIM.ORG article
Omim 606941
|
Update: 14. August 2020